Global HIV Vaccine Market Future Outlook
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Vaccine discovery, designing, research and development science is backed by several decades of knowledge. Every year, new vaccine for treating infectious diseases is entering in the market and their quality along with pharmacological efficacy is increasing. Innovative modalities have been found and market is overcrowded with the number of vaccines for different infectious diseases. In this scenario, absence of HIV vaccines becomes a pertinent question in front of investigators funded by both pharmaceutical companies and medical regulatory authorities. Gravity of the situation could also be understood by the fact that HIV clinical trials have failed to produce pharmacological benefits despite availability of suitable infrastructure. Simultaneously, HIV incidences are escalating tremendously across the globe due to which necessity for this vaccine is becoming more essential. All these facts support the imminent market introduction of HIV vaccines in global market to prevent progression and proliferation of AIDS epidemic.
Clinical trials are being done for across the globe for development of HIV vaccines and these efforts have yielded significant results. Investigators have identified artificial molecules that could mimic the HIV infection as result of which immune system would be activated. Their efficacy has been proved and clinical trials using them have yet to instigate. Several different modalities are also under investigation which may lead to development of relatively high cure rates. Certain receptors are also under investigation which has been found to be involved during initial phase of HIV infection. Immunoglobins may also serve as an ideal candidate due to their involvement in immune system activation. Beside this, several innovative modalities has been proposed for the treatment of HIV and emphasis is being given on the development of prophylactic vaccines. Several lead molecules have been discovered and their pharmacological efficacy is under investigation. In this way, investigators are expected to find some worthy candidate to the development of HIV vaccine.
Recombinant DNA technologies and genetic engineering has been widely used for the development of vaccines for several infectious diseases. These technologies are also being used for the development of HIV vaccines that would be commercialized in global market in coming years. Genetic manipulation of HIV is under consideration to develop a strain which have all molecular signatures but no pathogenicity. This decoy strain will activate the immune system to develop active immunity. Novel modalities include, use of recombinant molecules having higher immune eliciting capabilities. Computerized simulations are also being used for analysis of obscure vaccine candidates having pharmaceutical potential. This technology is expected to decrease the valuable time and precious resources utilized in the screening of proposed candidate. Furthermore, investigators are developing methodologies to find the effect of HIV gene expression on nonpathogenic bacterial/viral vectors.
Pharmaceutical companies have recognized the dearth of effective HIV medications due to which they are investing significant amount on research and development of HIV vaccines. Various candidates are at different stages of clinical trials and they would be introduced in market in coming years. Technology is developing at rapid rates due to which screening of selected candidate is expected to take place at lesser time. In this way, market winding times are expected to decrease due to lesser time in developmental phases. Manufacturing capabilities are highly developed but some tweaking has to be done according to HIV pathogen. Significant development in recombinant DNA technology and genetic engineering is also expected to accelerate the rate of HIV vaccine development. Investigators are also expected to find new modalities that will help in checking the AIDS. In this way, future of HIV vaccines market looks optimistic and it may be commercialized in next 5-10 years.
'Global HIV Vaccine Market Future Outlook' Report Highlights:
Vaccine discovery, designing, research and development science is backed by several decades of knowledge. Every year, new vaccine for treating infectious diseases is entering in the market and their quality along with pharmacological efficacy is increasing. Innovative modalities have been found and market is overcrowded with the number of vaccines for different infectious diseases. In this scenario, absence of HIV vaccines becomes a pertinent question in front of investigators funded by both pharmaceutical companies and medical regulatory authorities. Gravity of the situation could also be understood by the fact that HIV clinical trials have failed to produce pharmacological benefits despite availability of suitable infrastructure. Simultaneously, HIV incidences are escalating tremendously across the globe due to which necessity for this vaccine is becoming more essential. All these facts support the imminent market introduction of HIV vaccines in global market to prevent progression and proliferation of AIDS epidemic.
Clinical trials are being done for across the globe for development of HIV vaccines and these efforts have yielded significant results. Investigators have identified artificial molecules that could mimic the HIV infection as result of which immune system would be activated. Their efficacy has been proved and clinical trials using them have yet to instigate. Several different modalities are also under investigation which may lead to development of relatively high cure rates. Certain receptors are also under investigation which has been found to be involved during initial phase of HIV infection. Immunoglobins may also serve as an ideal candidate due to their involvement in immune system activation. Beside this, several innovative modalities has been proposed for the treatment of HIV and emphasis is being given on the development of prophylactic vaccines. Several lead molecules have been discovered and their pharmacological efficacy is under investigation. In this way, investigators are expected to find some worthy candidate to the development of HIV vaccine.
Recombinant DNA technologies and genetic engineering has been widely used for the development of vaccines for several infectious diseases. These technologies are also being used for the development of HIV vaccines that would be commercialized in global market in coming years. Genetic manipulation of HIV is under consideration to develop a strain which have all molecular signatures but no pathogenicity. This decoy strain will activate the immune system to develop active immunity. Novel modalities include, use of recombinant molecules having higher immune eliciting capabilities. Computerized simulations are also being used for analysis of obscure vaccine candidates having pharmaceutical potential. This technology is expected to decrease the valuable time and precious resources utilized in the screening of proposed candidate. Furthermore, investigators are developing methodologies to find the effect of HIV gene expression on nonpathogenic bacterial/viral vectors.
Pharmaceutical companies have recognized the dearth of effective HIV medications due to which they are investing significant amount on research and development of HIV vaccines. Various candidates are at different stages of clinical trials and they would be introduced in market in coming years. Technology is developing at rapid rates due to which screening of selected candidate is expected to take place at lesser time. In this way, market winding times are expected to decrease due to lesser time in developmental phases. Manufacturing capabilities are highly developed but some tweaking has to be done according to HIV pathogen. Significant development in recombinant DNA technology and genetic engineering is also expected to accelerate the rate of HIV vaccine development. Investigators are also expected to find new modalities that will help in checking the AIDS. In this way, future of HIV vaccines market looks optimistic and it may be commercialized in next 5-10 years.
'Global HIV Vaccine Market Future Outlook' Report Highlights:
- Introduction to HIV Vaccines
- Issues Related to the Development of HIV Vaccines
- Parameters for Successful Commercialization of HIV Vaccines
- Global HIV Vaccines Market Opportunity Analysis
- Global HIV Vaccine Clinical Pipeline by Company & Phase
- Global HIV Vaccine Clinical Pipeline: 100 Vaccines
- Majority Vaccine in Preclinical Phase: 42 Vaccines
1. INTRODUCTION TO HIV VACCINES
2. ISSUES RELATED TO THE DEVELOPMENT OF HIV VACCINES
2.1 Lack of Antigenicity
2.2 HIV Polymorphism
2.3 High Mutation Rates
2.4 Compromised Immune System
2.5 Integration with DNA
3. PARAMETERS FOR SUCCESSFUL COMMERCIALIZATION OF HIV VACCINES
3.1 Long Term Efficacy
3.2 Reduced Transmission
3.3 Relapse Prevention
3.4 Cost Effectiveness
3.5 Manufacturing Scalability
4. MECHANISM OF HIV VACCINES
5. GLOBAL HIV VACCINES MARKET OPPORTUNITY ANALYSIS
5.1 Market Overview
5.2 HIV Vaccine Clinical Pipeline Overview
6. GLOBAL HIV INCIDENCE RATES
7. GLOBAL HIV VACCINE MARKET DYNAMICS
7.1 Funding Scenario for HIV Vaccine
7.2 Favorable Market Parameters
7.3 HIV Vaccines Commercialization Challenges
8. GLOBAL HIV VACCINES MARKET FUTURE PROSPECTS
9. GLOBAL HIV VACCINE CLINICAL PIPELINE BY COMPANY & PHASE
9.1 Research
9.2 Preclinical
9.3 Clinical
9.4 Phase-I
9.5 Phase-I/II
9.6 Phase-II
9.7 Phase-III
9.8 Preregistration
10. DISCONTINUED & SUSPENDED HIV VACCINES IN CLINICAL PIPELINE BY COMPANY & PHASE
10.1 Discontinued
10.2 Suspended
10.3 No Development Reported
11. COMPETITIVE LANDSCAPE
11.1 AlphaVax
11.2 Antigen Express
11.3 Argo Therapeutics
11.4 Bionor Pharmaceuticals
11.5 Celldex Therapeutics
11.6 FIT Biotech
11.7 Crucell Pharmaceutical
11.8 GeneCure
11.9 Genetic Immunity
11.10 GenVec
11.11 GeoVax Labs
11.12 Glaxo Smithkline
11.13 Immune Response BioPharma
11.14 Inovio Pharmaceuticals
11.15 Novartis
11.16 Oncolys Biopharma
11.17 PaxVax
11.18 Profectus Biosciences
11.19 Sanofi
11.20 TVAX Biomedical
2. ISSUES RELATED TO THE DEVELOPMENT OF HIV VACCINES
2.1 Lack of Antigenicity
2.2 HIV Polymorphism
2.3 High Mutation Rates
2.4 Compromised Immune System
2.5 Integration with DNA
3. PARAMETERS FOR SUCCESSFUL COMMERCIALIZATION OF HIV VACCINES
3.1 Long Term Efficacy
3.2 Reduced Transmission
3.3 Relapse Prevention
3.4 Cost Effectiveness
3.5 Manufacturing Scalability
4. MECHANISM OF HIV VACCINES
5. GLOBAL HIV VACCINES MARKET OPPORTUNITY ANALYSIS
5.1 Market Overview
5.2 HIV Vaccine Clinical Pipeline Overview
6. GLOBAL HIV INCIDENCE RATES
7. GLOBAL HIV VACCINE MARKET DYNAMICS
7.1 Funding Scenario for HIV Vaccine
7.2 Favorable Market Parameters
7.3 HIV Vaccines Commercialization Challenges
8. GLOBAL HIV VACCINES MARKET FUTURE PROSPECTS
9. GLOBAL HIV VACCINE CLINICAL PIPELINE BY COMPANY & PHASE
9.1 Research
9.2 Preclinical
9.3 Clinical
9.4 Phase-I
9.5 Phase-I/II
9.6 Phase-II
9.7 Phase-III
9.8 Preregistration
10. DISCONTINUED & SUSPENDED HIV VACCINES IN CLINICAL PIPELINE BY COMPANY & PHASE
10.1 Discontinued
10.2 Suspended
10.3 No Development Reported
11. COMPETITIVE LANDSCAPE
11.1 AlphaVax
11.2 Antigen Express
11.3 Argo Therapeutics
11.4 Bionor Pharmaceuticals
11.5 Celldex Therapeutics
11.6 FIT Biotech
11.7 Crucell Pharmaceutical
11.8 GeneCure
11.9 Genetic Immunity
11.10 GenVec
11.11 GeoVax Labs
11.12 Glaxo Smithkline
11.13 Immune Response BioPharma
11.14 Inovio Pharmaceuticals
11.15 Novartis
11.16 Oncolys Biopharma
11.17 PaxVax
11.18 Profectus Biosciences
11.19 Sanofi
11.20 TVAX Biomedical
LIST OF FIGURES
Figure 1-1: Effects of HIV Disease
Figure 1-2: Methods of HIV Transmission
Figure 1-3: Modalities to Treat HIV Infection
Figure 2-1: Issues Related to the Development of HIV Vaccines
Figure 3-1: Requirements for Successful Commercialization of HIV Vaccines
Figure 4-1: Types of HIV Vaccines
Figure 4-2: Techniques to Develop HIV Vaccines
Figure 4-3: Mechanism of SAV001 Vaccine
Figure 4-4: Mechanism of AIDSVAX HIV Vaccine
Figure 4-5: Mechanism of V520 HIV Vaccine
Figure 5-1: HIV Vaccine Clinical Pipeline by Phase (%), 2015
Figure 5-2: HIV Vaccine Clinical Pipeline by Phase (Number), 2015
Figure 5-3: No Development Reported HIV Vaccine Clinical Pipeline by Phase (%), 2015
Figure 5-4: No Development Reported HIV Vaccine Clinical Pipeline by Phase (Number), 2015
Figure 5-5: Discontinued HIV Vaccine Clinical Pipeline by Phase (%), 2015
Figure 5-6: Discontinued HIV Vaccine Clinical Pipeline by Phase (Number), 2015
Figure 6-1: People Living With HIV Infection (Million), 2009-2014
Figure 6-2: New Incidence of HIV Infection (Million), 2009-2012
Figure 7-1: Global HIV Vaccines R&D Funding (US$ Million), 2005–2012
Figure 7-2: Global HIV Vaccines R&D Funding Breakup (%), 2012
Figure 7-3: Philanthropic Sector Spending on HIV Vaccines by Clinical Research Phase (%), 2012
Figure 7-4: HIV Vaccine Market Favorable Parameters
Figure 7-5: HIV Vaccines Commercialization Challenges
Figure 8-1: Estimated HIV Market Size with Routine Vaccination Only
Figure 11-1: AlphaVax Clinical Pipeline
Figure 11-2: Bionor Pharma Clinical Pipeline
Figure 11-3: TVAX Biomedical Clinical Pipeline
Figure 1-1: Effects of HIV Disease
Figure 1-2: Methods of HIV Transmission
Figure 1-3: Modalities to Treat HIV Infection
Figure 2-1: Issues Related to the Development of HIV Vaccines
Figure 3-1: Requirements for Successful Commercialization of HIV Vaccines
Figure 4-1: Types of HIV Vaccines
Figure 4-2: Techniques to Develop HIV Vaccines
Figure 4-3: Mechanism of SAV001 Vaccine
Figure 4-4: Mechanism of AIDSVAX HIV Vaccine
Figure 4-5: Mechanism of V520 HIV Vaccine
Figure 5-1: HIV Vaccine Clinical Pipeline by Phase (%), 2015
Figure 5-2: HIV Vaccine Clinical Pipeline by Phase (Number), 2015
Figure 5-3: No Development Reported HIV Vaccine Clinical Pipeline by Phase (%), 2015
Figure 5-4: No Development Reported HIV Vaccine Clinical Pipeline by Phase (Number), 2015
Figure 5-5: Discontinued HIV Vaccine Clinical Pipeline by Phase (%), 2015
Figure 5-6: Discontinued HIV Vaccine Clinical Pipeline by Phase (Number), 2015
Figure 6-1: People Living With HIV Infection (Million), 2009-2014
Figure 6-2: New Incidence of HIV Infection (Million), 2009-2012
Figure 7-1: Global HIV Vaccines R&D Funding (US$ Million), 2005–2012
Figure 7-2: Global HIV Vaccines R&D Funding Breakup (%), 2012
Figure 7-3: Philanthropic Sector Spending on HIV Vaccines by Clinical Research Phase (%), 2012
Figure 7-4: HIV Vaccine Market Favorable Parameters
Figure 7-5: HIV Vaccines Commercialization Challenges
Figure 8-1: Estimated HIV Market Size with Routine Vaccination Only
Figure 11-1: AlphaVax Clinical Pipeline
Figure 11-2: Bionor Pharma Clinical Pipeline
Figure 11-3: TVAX Biomedical Clinical Pipeline
LIST OF TABLES
Table 4-1: HIV Vaccine Antigens under Investigation
Table 6-1: Comparative Analysis of HIV Associated Features across the Globe
Table 7-1: HIV Vaccines Funding by Sector (US$ Million), 2006-2012
Table 8-1: Global Impact of a Vaccine on AIDS Incidence and Mortality
Table 4-1: HIV Vaccine Antigens under Investigation
Table 6-1: Comparative Analysis of HIV Associated Features across the Globe
Table 7-1: HIV Vaccines Funding by Sector (US$ Million), 2006-2012
Table 8-1: Global Impact of a Vaccine on AIDS Incidence and Mortality
